Last Updated : January 31, 2025
Details
Generic Name:
pembrolizumab
Project Status:
Pending
Therapeutic Area:
Head and neck squamous cell carcinoma
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC410-000
Call for patient/clinician input closed:
Tumour Type:
Head and Neck
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without platinum-containing chemotherapy and then as monotherapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without platinum-containing chemotherapy and then as monotherapy.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 31, 2025